Treatment Implementation and Long-Term Considerations in BPDCN
Panelists discuss how optimizing shared-care models between academic and community centers enhances continuity in complex hematologic malignancies. Key monitoring parameters for tagraxofusp include capillary leak syndrome risk. Timely transplant referral depends on disease kinetics. Novel therapies are among the unmet needs in plasmacytoid dendritic cell neoplasm. Support resources aid patient management. Emerging treatments and clinical insights continue to advance care.
Video content above is prompted by the following:
- What are effective strategies to structure the shared-care model between academic and community centers?
- What specific parameters are critical to monitor when using tagraxofusp in the community setting?
- What factors influence the timing of transplant referral in patients who achieve complete response with initial therapy?
- What unmet needs remain in managing blastic plasmacytoid dendritic cell neoplasm(BPDCN)?
- What are resources/support systems for patients with complex hematologic malignancies?
- What clinical pearls and up-and-coming treatment strategies are you excited about?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
